{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:46:31Z","timestamp":1791240391374,"version":"4.1.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.pathol.2022.11.005","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T16:16:48Z","timestamp":1671553008000},"page":"227-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Regression in cutaneous melanoma: histological assessment, immune mechanisms and clinical implications"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5368-4248","authenticated-orcid":false,"given":"Karina","family":"Aivazian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2022.11.005_bib1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nrc1782","article-title":"Paradoxical roles of the immune system during cancer development","volume":"6","author":"Visser","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pathol.2022.11.005_bib2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/00000441-189305000-00001","article-title":"The treatment of malignant tumors by repeated inoculations of erysipelas with a report of ten original cases. 1893","volume":"105","author":"Coley","year":"1991","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.pathol.2022.11.005_bib3","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/postgradmedj\/79.938.672","article-title":"Dr William Coley and tumour regression : a place in history or in the future","volume":"79","author":"Cann","year":"2003","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.pathol.2022.11.005_bib4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1749-6632.1964.tb40991.x","article-title":"Spontaneous regression of cancer","volume":"114","author":"Everson","year":"1964","journal-title":"Ann New York Acad Sci"},{"key":"10.1016\/j.pathol.2022.11.005_bib5","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/1097-0142(195309)6:5<1040::AID-CNCR2820060525>3.0.CO;2-5","article-title":"Spontaneous regression of melanoma","volume":"6","author":"Sumner","year":"1953","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2022.11.005_bib6","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/1097-0142(19920315)69:6<1377::AID-CNCR2820690613>3.0.CO;2-N","article-title":"Regression of primary melanoma with metastases","volume":"69","author":"Avril","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2022.11.005_bib7","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0140-6736(81)92359-X","article-title":"Malignant melanoma in renal-transplant recipients","volume":"317","author":"Greene","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2022.11.005_bib8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2174\/157488812799859883","article-title":"Immunotherapy for malignant melanoma","volume":"7","author":"Zeiser","year":"2012","journal-title":"Curr Stem Cell Res Ther"},{"key":"10.1016\/j.pathol.2022.11.005_bib9","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.semcancer.2019.08.002","article-title":"Seminars in cancer biology unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment","volume":"59","author":"Marzagalli","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.pathol.2022.11.005_bib10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2559.1992.tb00988.x","article-title":"Histological regression in primary cutaneous melanoma: recognition, prevalence and significance","volume":"20","author":"Blessing","year":"1992","journal-title":"Histopathology"},{"key":"10.1016\/j.pathol.2022.11.005_bib11","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/jnci\/81.24.1893","article-title":"Model predicting survival in stage I melanoma based on tumor progression","volume":"81","author":"Clark","year":"1989","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.pathol.2022.11.005_bib12","series-title":"Protocol for the Examination of Biopsy Specimens From Patients with Melanoma of the Skin. Version: Melanoma Biopsy 4.1.0.0. College of American Pathologists","author":"Shon","year":"2021"},{"key":"10.1016\/j.pathol.2022.11.005_bib13","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1600-0560.2010.01531.x","article-title":"Elastic fiber pattern in regressing melanoma: a histochemical and immunohistochemical study","volume":"37","author":"Kamino","year":"2010","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.pathol.2022.11.005_bib14","first-page":"145","article-title":"Spectrum of morphologic alterations of regression in cutaneous melanoma - potential for improving disease prognosis","volume":"50","author":"Zurac","year":"2012","journal-title":"Rom J Intern Med"},{"key":"10.1016\/j.pathol.2022.11.005_bib15","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/DAD.0b013e318165641a","article-title":"Complete regression of primary malignant melanoma","volume":"30","author":"Emanuel","year":"2008","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.pathol.2022.11.005_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.pathol.2019.01.008","article-title":"Cutaneous tumoural melanosis: a presentation of complete regression of cutaneous melanoma","volume":"51","author":"Ching","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2022.11.005_bib17","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1111\/jdv.13815","article-title":"Regression in cutaneous melanoma: a comprehensive review from diagnosis to prognosis","volume":"30","author":"Ribero","year":"2016","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.pathol.2022.11.005_bib18","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1600-0560.1993.tb00228.x","article-title":"Histologic regression in malignant melanoma: an interobserver concordance study","volume":"20","author":"Kang","year":"1993","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.pathol.2022.11.005_bib19","first-page":"759","article-title":"Problems in defining melanoma regression and prognostic implication","volume":"100","author":"Requena","year":"2009","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Ed)"},{"key":"10.1016\/j.pathol.2022.11.005_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41379-019-0402-x","article-title":"Melanoma pathology reporting and staging","volume":"33","author":"Scolyer","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2022.11.005_bib21","first-page":"1","article-title":"Grey-blue regression in melanoma in situ\u2014evaluation on 111 cases","volume":"2011","author":"Bassoli","year":"2011","journal-title":"J\u00a0Skin Cancer"},{"key":"10.1016\/j.pathol.2022.11.005_bib22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00403-020-02106-w","article-title":"Reporting regression with melanoma in situ : reappraisal of a potential paradox","volume":"313","author":"Cartron","year":"2021","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.pathol.2022.11.005_bib23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF00707986","article-title":"Partial regression in thin primary cutaneous malignant melanomas clinical stage I","volume":"408","author":"S\u00f8ndergaard","year":"1985","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"10.1016\/j.pathol.2022.11.005_bib24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.pathol.2022.11.005_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.02105","article-title":"Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma","volume":"11","author":"Maibach","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.pathol.2022.11.005_bib26","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pathol.2022.11.005_bib27","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11912-008-0067-y","article-title":"Melanoma and the tumor microenvironment","volume":"10","author":"Villanueva","year":"2008","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.pathol.2022.11.005_bib28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/pcmr.12926","article-title":"The tumour immune landscape and its implications in cutaneous melanoma","volume":"34","author":"Attrill","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.pathol.2022.11.005_bib29","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1158\/2159-8290.CD-19-0015","article-title":"Cellular plasticity in cancer","volume":"9","author":"Yuan","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pathol.2022.11.005_bib30","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.cell.2016.01.049","article-title":"The basis of oncoimmunology","volume":"164","author":"Palucka","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.pathol.2022.11.005_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.pathol.2022.11.005_bib32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.pathol.2022.11.005_bib33","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/2326-6066.CIR-13-0216","article-title":"CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful","volume":"2","author":"Kim","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.pathol.2022.11.005_bib34","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jss.2007.03.053","article-title":"Melanoma induces immunosuppression by up-regulating FOXP3+ regulatory T cells","volume":"141","author":"Baumgartner","year":"2007","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.pathol.2022.11.005_bib35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res"},{"key":"10.1016\/j.pathol.2022.11.005_bib36","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1002\/1521-4141(200109)31:9<2547::AID-IMMU2547>3.0.CO;2-J","article-title":"Induction of antigen-specific human CD4+ T cell anergy by peripheral blood DC2 precursors","volume":"31","author":"Kuwana","year":"2001","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.pathol.2022.11.005_bib37","first-page":"4155","article-title":"Tumor infiltrating lymphocytes : the regulator of melanoma evolution (review)","volume":"17","author":"Antohe","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.pathol.2022.11.005_bib38","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.immuni.2010.12.011","article-title":"CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens","volume":"34","author":"Asano","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.pathol.2022.11.005_bib39","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated mactophages inhibits phagocytosis and tumor immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2022.11.005_bib40","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/(SICI)1097-0215(20000115)85:2%3C182::AID-IJC6%3E3.0.CO;2-M","article-title":"Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNF\u03b1 and IL-1\u03b1","volume":"85","author":"Torisu","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pathol.2022.11.005_bib41","first-page":"5399","article-title":"Macrophages in skin melanoma-the key element in melanomagenesis (review)","volume":"15","author":"Pieniazek","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.pathol.2022.11.005_bib42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4049\/jimmunol.1500055","article-title":"CD11c-expressing B cells are located at the T cell\/B cell border in spleen and are potent APCs","volume":"195","author":"Rubtsov","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.pathol.2022.11.005_bib43","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.4049\/jimmunol.0903009","article-title":"B\u00a0cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletione enhances B16 melanoma growth in mice","volume":"184","author":"DiLillo","year":"2010","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.pathol.2022.11.005_bib44","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2022.11.005_bib45","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3389\/fimmu.2015.00649","article-title":"Natural killer cell recognition of melanoma: new clues for a more effective immunotherapy","volume":"6","author":"Tarazona","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.pathol.2022.11.005_bib46","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3389\/fonc.2020.00722","article-title":"Metabolic plasticity of melanoma cells and their crosstalk with tumor microenvironment","volume":"10","author":"Avagliano","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.pathol.2022.11.005_bib47","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3390\/cells9051151","article-title":"Functional roles of matrix metalloproteinases and their inhibitors in melanoma","volume":"9","author":"Napoli","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.pathol.2022.11.005_bib48","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.3892\/ol.2016.4391","article-title":"Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors","volume":"11","author":"Zurac","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1016\/j.pathol.2022.11.005_bib49","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1158\/1078-0432.CCR-05-2616","article-title":"Well-defined melanoma antigens as progression markers for melanoma : insights into differential expression and host response based on stage","volume":"12","author":"Hodi","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2022.11.005_bib50","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/pcmr.12459","article-title":"The genomic landscape of cutaneous melanoma","volume":"29","author":"Zhang","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.pathol.2022.11.005_bib51","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/15384047.2017.1323596","article-title":"Immune surveillance in melanoma: from immune attack to melanoma escape and even counterattack","volume":"18","author":"Mahmoud","year":"2017","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.pathol.2022.11.005_bib52","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1600-0625.2008.00779.x","article-title":"Immune modulation by melanoma-derived factors","volume":"17","author":"Ilkovitch","year":"2008","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.pathol.2022.11.005_bib53","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/pcmr.12513","article-title":"Bidirectional cross talk between patient-derived melanoma and cancer-associated fibroblasts promotes invasion and proliferation","volume":"29","author":"Izar","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.pathol.2022.11.005_bib54","doi-asserted-by":"crossref","first-page":"7255","DOI":"10.3390\/ijms22147255","article-title":"Profiling cancer-associated fibroblasts in melanoma","volume":"22","author":"Papaccio","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pathol.2022.11.005_bib55","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.pathol.2022.11.005_bib56","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","article-title":"Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies","volume":"31","author":"Anderson","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pathol.2022.11.005_bib57","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/path.1494","article-title":"Presence and localization of T-cell subsets in relation to melanocyte differentiation antigen expression and tumour regression as assessed by immunohistochemistry and molecular analysis of microdissected T cells","volume":"202","author":"Bernsen","year":"2004","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.pathol.2022.11.005_bib58","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1172\/JCI116278","article-title":"Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion","volume":"91","author":"Ferradini","year":"1993","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pathol.2022.11.005_bib59","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/DAD.0000000000000205","article-title":"Study of the immunophenotype of the inflammatory cells in melanomas with regression and halo nevi","volume":"37","author":"Botella-estrada","year":"2015","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.pathol.2022.11.005_bib60","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CMR.0000000000000331","article-title":"The microenvironment in primary cutaneous melanoma with associated spontaneous tumor regression: evaluation for T-regulatory cells and the presence of an immunosuppressive microenvironment","volume":"27","author":"Gray","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.pathol.2022.11.005_bib61","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.pathol.2019.04.001","article-title":"Phenotypic characterisation of immune cells associated with histological regression in cutaneous melanoma","volume":"51","author":"Osella-Abate","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2022.11.005_bib62","article-title":"FOXP3 in melanoma with regression: between tumoral expression and regulatory t cell upregulation","volume":"2020","author":"Cioplea","year":"2020","journal-title":"J\u00a0Immunol Res"},{"key":"10.1016\/j.pathol.2022.11.005_bib63","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/1523-1747.ep12292705","article-title":"T\u00a0helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas","volume":"108","author":"Lowes","year":"1997","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.pathol.2022.11.005_bib64","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/jdv.16784","article-title":"Microenvironment in cutaneous melanomas : a gene expression profile study may explain the role of histological regression","volume":"35","author":"Osella-Abate","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.pathol.2022.11.005_bib65","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.53008","article-title":"Functional heterogeneity of lymphocytic patterns in primary melanoma dissected through single-cell multiplexing","volume":"9","author":"Bosisio","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.pathol.2022.11.005_bib66","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/00000658-197511000-00007","article-title":"Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma","volume":"182","author":"Breslow","year":"1975","journal-title":"Ann Surg"},{"key":"10.1016\/j.pathol.2022.11.005_bib67","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00000637-199201000-00023","article-title":"\u201cThin\u201d malignant melanoma: risk factors and clinical management","volume":"28","author":"Slingluff","year":"1992","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.pathol.2022.11.005_bib68","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2559.1989.tb03076.x","article-title":"Thin regressing malignant melanoma: significance of concurrent regional lymph node metastases","volume":"15","author":"Shaw","year":"1989","journal-title":"Histopathology"},{"key":"10.1016\/j.pathol.2022.11.005_bib69","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/CMR.0b013e32834dd003","article-title":"Regression does not significantly underestimate melanoma thickness","volume":"22","author":"Traves","year":"2012","journal-title":"Melanoma Res"},{"key":"10.1016\/j.pathol.2022.11.005_bib70","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaad.2018.06.054","article-title":"Prognostic impact of regression in patients with primary cutaneous melanoma >1 mm in thickness","volume":"80","author":"Ribero","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.pathol.2022.11.005_bib71","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1177\/000313481107700819","article-title":"Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma","volume":"77","author":"Burton","year":"2011","journal-title":"Am Surg"},{"key":"10.1016\/j.pathol.2022.11.005_bib72","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.12659\/MSM.905862","article-title":"Regression and sentinel lymph node status in melanoma progression","volume":"24","author":"Letca","year":"2018","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.pathol.2022.11.005_bib73","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/CMR.0000000000000277","article-title":"Presence of histological regression as a prognostic factor in cutaneous melanoma patients","volume":"26","author":"Tas","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.pathol.2022.11.005_bib74","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1245\/s10434-021-11251-z","article-title":"Is there a relationship between TILs and regression in melanoma","volume":"29","author":"Morrison","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.pathol.2022.11.005_bib75","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jss.2021.05.008","article-title":"A\u00a0retrospective, observational analysis of tumor infiltrating lymphocytes and tumor regression in melanoma","volume":"267","author":"Zaladonis","year":"2021","journal-title":"J\u00a0Surg Res"},{"key":"10.1016\/j.pathol.2022.11.005_bib76","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/modpathol.2012.43","article-title":"Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node","volume":"25","author":"Ma","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2022.11.005_bib77","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/bjc.2017.397","article-title":"Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients","volume":"118","author":"Zugna","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pathol.2022.11.005_bib78","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.surg.2021.05.010","article-title":"Regression is significantly associated with outcomes for patients with melanoma","volume":"170","author":"Subramanian","year":"2021","journal-title":"Surgery"},{"key":"10.1016\/j.pathol.2022.11.005_bib79","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/jamadermatol.2020.5032","article-title":"Association of histologic regression with a favorable outcome in patients with stage 1 and stage 2 cutaneous melanoma","volume":"157","author":"El Sharouni","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.pathol.2022.11.005_bib80","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjd.15552","article-title":"Prognostic role of histological regression in primary cutaneous melanoma: a systematic review and meta-analysis","volume":"178","author":"Gualano","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.pathol.2022.11.005_bib81","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1001\/jamadermatol.2015.2235","article-title":"Association of histologic regression in primary melanoma with sentinel lymph node status: a systematic review and meta-analysis","volume":"151","author":"Ribero","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.pathol.2022.11.005_bib82","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/jcp.2007.049411","article-title":"The correlation of regression in primary melanoma with sentinel lymph node status","volume":"61","author":"Kaur","year":"2008","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.pathol.2022.11.005_bib83","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1245\/s10434-011-1826-9","article-title":"Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database","volume":"18","author":"White","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.pathol.2022.11.005_bib84","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1046\/j.1365-2133.2003.05502.x","article-title":"Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas","volume":"149","author":"Ol\u00e1h","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.pathol.2022.11.005_bib85","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s12253-019-00769-z","article-title":"Is it necessary to perform sentinel lymph node biopsy in thin melanoma? A retrospective single center analysis","volume":"26","author":"Kocsis","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.pathol.2022.11.005_bib86","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.19.01902","article-title":"Factors affecting sentinel node metastasis in thin (T1) cutaneous melanomas: development and external validation of a predictive nomogram","volume":"38","author":"Maurichi","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.005_bib87","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/s41379-021-00870-2","article-title":"Histological regression in melanoma: impact on sentinel lymph node status and survival","volume":"34","author":"Aivazian","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2022.11.005_bib88","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1007\/s00432-021-03565-y","article-title":"Coexistence of regression and tumor infiltrating lymphocytes is associated with more favorable survival in melanoma","volume":"147","author":"Tas","year":"2021","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.005_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2019.1593806","article-title":"Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis","volume":"8","author":"Fu","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.pathol.2022.11.005_bib90","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1200\/JCO.2013.51.3002","article-title":"Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study","volume":"31","author":"Thomas","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.005_bib91","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","article-title":"Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma","volume":"30","author":"Azimi","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.005_bib92","first-page":"1","article-title":"Prognostic significance of primary tumor-infiltrating lymphocytes in a contemporary melanoma cohort","volume":"29","author":"Straker","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.pathol.2022.11.005_bib93","first-page":"2700","article-title":"The value of tumor infiltrating lymphocytes as prognostic factor for lymph node status and survival amongst patients with cutaneous malignant melanoma","volume":"25","author":"Gata","year":"2020","journal-title":"J\u00a0BUON"},{"key":"10.1016\/j.pathol.2022.11.005_bib94","first-page":"1","article-title":"Assessing the prognostic significance of tumor-infiltrating lymphocytes in patients with melanoma using pathologic features identified by natural language processing","volume":"4","author":"Yang","year":"2021","journal-title":"JAMA Newt Open"},{"key":"10.1016\/j.pathol.2022.11.005_bib95","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00403-020-02067-0","article-title":"High level of TILs is an independent predictor of negative sentinel lymph node in women but not in men","volume":"313","author":"Fortes","year":"2021","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.pathol.2022.11.005_bib96","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/cncr.21283","article-title":"The predictive value of CD8, CD4, CD68 and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase","volume":"104","author":"Piras","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2022.11.005_bib97","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/cncr.26511","article-title":"Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I\/II melanoma","volume":"118","author":"Jensen","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2022.11.005_bib98","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1158\/1078-0432.CCR-1161-03","article-title":"T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma","volume":"10","author":"Lad\u00e1nyi","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2022.11.005_bib99","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/ijc.23543","article-title":"Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression","volume":"615","author":"Houdt","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pathol.2022.11.005_bib100","first-page":"1","article-title":"Significance of primary melanoma regression on local infiltrate and outcome","volume":"12","author":"Kelati","year":"2022","journal-title":"Dermatol Pract Concept"},{"key":"10.1016\/j.pathol.2022.11.005_bib101","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.humpath.2016.07.008","article-title":"Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma","volume":"57","author":"Weiss","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.pathol.2022.11.005_bib102","first-page":"1115","article-title":"Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma","volume":"18","author":"Miracco","year":"2007","journal-title":"Oncol Rep"},{"key":"10.1016\/j.pathol.2022.11.005_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.561390","article-title":"Peritumoral immune infiltrate as a prognostic biomarker in thin melanoma","volume":"11","author":"Sabbatino","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.pathol.2022.11.005_bib104","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12253-010-9254-x","article-title":"FOXP3\u00a0+ cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma","volume":"16","author":"Lad\u00e1nyi","year":"2010","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.pathol.2022.11.005_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.979993","article-title":"Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome","volume":"13","author":"Attrill","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.pathol.2022.11.005_bib106","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CMR.0b013e32832eabd5","article-title":"Spontaneous regression of metastases from melanoma: review of the literature","volume":"19","author":"Kalialis","year":"2009","journal-title":"Melanoma Res"},{"key":"10.1016\/j.pathol.2022.11.005_bib107","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.005_bib108","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for melanoma patients","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2022.11.005_bib109","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrc2355","article-title":"Adoptive cell transfer: a clinical path to effective cancer immunotherapy","volume":"8","author":"Rosenberg","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pathol.2022.11.005_bib110","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2022.11.005_bib111","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2022.11.005_bib112","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2022.11.005_bib113","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2022.11.005_bib114","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2022.11.005_bib115","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi5072","article-title":"Spatially mapping the immune landscape of melanoma using imaging mass cytometry","volume":"7","author":"Moldoveanu","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.pathol.2022.11.005_bib116","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.3390\/ijms20225731","article-title":"Melanoma and vitiligo: in good company","volume":"20","author":"Failla","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pathol.2022.11.005_bib117","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.pathol.2022.11.005_bib118","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III\u2013IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2022.11.005_bib119","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.866703","article-title":"Networks of CD8\u00a0+ T cell response activation in melanoma and vitiligo","volume":"13","author":"Fukuda","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.pathol.2022.11.005_bib120","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1755-148X.2010.00703.x","article-title":"First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi","volume":"23","author":"van Geel","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.pathol.2022.11.005_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.110019","article-title":"Histological regression in primary melanoma and drug-related immune reaction towards metastatic melanoma: are they associated?","volume":"143","author":"Ribero","year":"2020","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.pathol.2022.11.005_bib122","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/ced.14329","article-title":"Reporting regression in primary cutaneous melanoma. Part 2: prognosis, evaluation and management","volume":"45","author":"Cartron","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.pathol.2022.11.005_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.636681","article-title":"Multiplexed immunohistochemistry and digital pathology as the foundation for next-generation pathology in melanoma: methodological comparison and future clinical applications","volume":"11","author":"Van Herck","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.pathol.2022.11.005_bib124","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","article-title":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","volume":"29","author":"Tetzlaff","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302522003166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302522003166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T13:41:29Z","timestamp":1710510089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302522003166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":124,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0031302522003166"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2022.11.005","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regression in cutaneous melanoma: histological assessment, immune mechanisms and clinical implications","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2022.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}